Alnylam Pharmace. buy William Blair
Start price
25.07.23
/
50%
€175.00
Target price
25.07.24
-
Performance (%)
25.14%
End price
26.07.24
€219.00
Summary
This prediction ended on 26.07.24 with a price of €219.00. The prediction had a final performance of 25.14%. William_Blair has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. William_Blair has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | 6.196% | 6.196% | 42.166% |
| iShares Core DAX® | 1.887% | 1.967% | 17.000% |
| iShares Nasdaq 100 | 2.316% | -1.227% | 22.986% |
| iShares Nikkei 225® | 1.134% | 0.390% | 9.520% |
| iShares S&P 500 | 1.821% | 0.790% | 22.957% |
Comments by William_Blair for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for ALNY provided by MarketBeat
In the thread Trading Alnylam Pharmace.
Die von William_Blair gewählte maximale Laufzeit wurde überschritten